T1	Participants 17 58	patients with non-small cell lung cancer:
T2	Participants 119 153	non-small cell lung cancer (NSCLC)
T3	Participants 604 705	381 patients were randomised to chemotherapy (C, 192 patients) or no chemotherapy (NoC, 189 patients)
